Is Cara Therapeutics a Buy?
With the clinical trial process in the rearview mirror, a lot of the risks associated with development are in the past, leaving "only" the risks of competing profitably. Such is the situation of Cara Therapeutics (NASDAQ: CARA), which is developing a drug called Korsuva to treat pruritus. You've probably experienced pruritus (at least to a small degree) before, because it's the sensation of itchiness.